Structural, Functional and Therapeutic Aspects of Snake Venom Metal- Loproteinases

Total Page:16

File Type:pdf, Size:1020Kb

Structural, Functional and Therapeutic Aspects of Snake Venom Metal- Loproteinases Send Orders for Reprints to [email protected] 28 Mini-Reviews in Organic Chemistry, 2014, 11, 28-44 Structural, Functional and Therapeutic Aspects of Snake Venom Metal- loproteinases P. Chellapandi* Department of Bioinformatics, School of Life Sciences, Bharathidasan University, Tiruchirappalli-620024, Tamil Nadu, India Abstract: Snake venoms are rich sources of metalloproteinases that are of biological interest due to their diverse molecu- lar diversity and selective therapeutic applications. Snake venoms metalloproteinases (SVMPs) belong to the MEROPS peptidase family M12B or reprolysin subfamily, which are consisted of four major domains include a reprolysin catalytic domain, a disintegrin domain, a reprolysin family propeptide domain and a cysteine-rich domain. The appropriate struc- tural and massive sequences information have been available for SVMPs family of enzymes in the Protein Data Bank and National Center for Biotechnology Information, respectively. Functional essentiality of every domain and a crucial contri- bution of binding geometry, primary specificity site, and structural motifs have been studied in details, pointing the way for designing potential anti-coagulation, antitumor, anti-complementary and anti-inflammatory drugs or peptides. These enzymes have been reported to degrade fibrinogen, fibrin and collagens, and to prevent progression of clot formation. An- giotensin-converting enzyme activity, antibacterial properties, haemorrhagic activity and platelet aggregation response of SVMPs have been studied earlier. Structural information of these enzymes together with recombinant DNA technology would strongly promote the construction of many recombinant therapeutic peptides, particularly fibrinogenases and vac- cines. We have comprehensively reviewed the structure-function-evolution relationships of SVMPs family proteins and their advances in the promising target models for structure-based inhibitors and peptides design. Moreover, structure- function-evolution integrity of metalloproteinase from Gloydius halys venom was preliminarily analyzed herein that may provide a conceptual idea for the future of antibacterial peptide design. Keywords: Reprolysin, Bioactive peptides, Family M12B, ADAMs, Adamalysin, Antimicrobial activity, Metalloproteinase, Snake venoms. 1. INTRODUCTION charged amino acid side chains are ligands for the metal ions in the binding packet. Side chain residues His, Glu, Asp or Proteinase is a hydrolytic enzyme that begins the Lys are the known metal ligands and at least one other hydrolytic breakdown of proteins and peptides, usually by residue (Glu) are required for catalysis [1]. splitting them into polypeptide chains. It occurs in all living kingdoms involving in major physiological phenomena. Proteomic study on snake venom proteins reported the Proteinase family can be classified into five major groups SVMPs belong to the MEROPS peptidase family M12B or based on the catalytic residue viz. serine, threonine, cysteine, reprolysin subfamily [10]. M12B reprolysin subfamily exists aspartate and metal-binding sites [1]. A significant pro- in a majority of snake venoms (Fig. 1). The current portion of serine and metalloproteinases present in snake bioinformatics data on reprolysin subfamily M12B pointed venoms proteins that are typically used in traditional out that there are 148, 145 and 122 species having reprolysin medicine or therapeutics [2-6]. Nevertheless, the majority of (PF01421), reprolysin propeptide (PF01562) and ADAMs snakes have metalloproteinases in the venoms for their (A Disintegrin And Metalloproteinase) cysteine-rich pathophysiological functions in the bitten preys [7]. (PF08516) subfamilies, respectively. Among Colubroidea superfamily (all snakes belong to this superfamily), a Snake venom metalloproteinases (SVMPs) are part of the predominant existence of reprolysin subfamily is reported in metzincin family of zinc-dependent metalloproteinases the venoms of Crotalinae family and then in the venoms of consisting of an identical zinc-dependent motif HEX- Elapidae family. A limited study has been done on the XHXXGXXH and of a methionine turn [8]. Matrixin, astacin reprolysin subfamily in the venoms of Atractaspididae and serralysin are other parts of metzincin family [9]. A family. The protein sequences deposited for reprolysin zincin-like fold is common in SVMPs so that Zn2+ ion takes subfamily in Viperinae family venoms are accounted to be a major role in the catalysis of the hydrolysis of internal, more than in the venoms of Crotalinae family. It suggests the alpha-peptide bonds in a polypeptide chain. One or two advantages of using SVMPs from Viperinae family showing metal ions hold the water molecule (as a nucleophile) and a vital importance in therapeutic and medical applications. Brevilysin H6, acutolysin, bilitoxin, leucolysin, *Address correspondence to this author at the Department of Bioinformatics, jararhagin, bothrolysin, bothropasin, adamalysin, atrolysin A, School of Life Sciences, Bharathidasan University, Tiruchirappalli-620024, atroxase, basilysin, horrilysin, ruberlysin, trimerelysin, Tamil Nadu, India; Tel: +91-431-2407071; Fax:+91-431-2407045; E-mail: [email protected] russellysin, cobrin, najalysin and catrocollastatin are some 1875-6298/14 $58.00+.00 © 2014 Bentham Science Publishers Structural, Functional and Therapeutic Aspects of Snake Venom Metalloproteinases Mini-Reviews in Organic Chemistry, 2014, Vol. 11, No. 1 29 Fig. (1). Dispersion of snake venom metalloproteinases in Colubroidea superfamily. The above figure is represented the total number of species reported for the metalloproteinases and the below figure represents the total number protein sequence entries available in Pfam version 26.0 for Colubroidea superfamily. examples of SVMPs molecular diversity available in reprolysin subfamily has four different conserved domains: a MEROPS database [11]. Twenty eight structures of rep- reprolysin catalytic domain, a disintegrin domain, a rep- rolysin subfamily and 2 structures of ADAMs cysteine-rich rolysin family propeptide domain and an ADAMs cysteine- subfamily include with ligands have been deposited in the rich domain. A reprolysin is a main catalytic enzyme domain protein data bank (PDB) to date. Thus, overwhelming bioin- involving in Zn2+ ion binding and peptide cleavage activity. formatics resources, crystallographic structural information Disintegrin is a small domain typically with an Arg-Gly-Asp and literature records for SVMPs family of enzymes are recognition sequence on a disintegrin-loop that inhibits collectively support the identification, designing and platelet aggregation via integrin binding. Reprolysin family development of therapeutic compounds or peptides from the propeptide domain is the propeptide for members of snake venom sources. peptidase family M12B. The propeptide contains a sequence motif similar to the "cysteine switch" of the matrixins [13- 2. FUNCTIONAL DOMAINS 15]. The last domain, adamalysin (ADAMs), is membrane- bound zinc containing metalloproteinase, which is con- SVMPs are classified into three types (P-I to P-III) based sidered to be crucial modulators of physiological and patho- on their conserved domain architecture [5, 12]. M12B 30 Mini-Reviews in Organic Chemistry, 2014, Vol. 11, No. 1 P. Chellapandi (A) (B) Fig. (2). Topological view of conserved domains identified in metalloproteinase of G. halys (2a) and WebLogo representation of the conserved functional motifs identified across the peptidase M12B family (2b). physiological processes [16]. The residues that are important the molecule [22, 23]. Such multiple functional motifs in the for stabilizing domains architecture are strictly conserved metalloproteinase of G. halys may influence its binding cleft throughout the primary structure among SVMPs [17]. orientation on bacterial membrane proteins. Reprolysin, disintegrin and ADAM cysteine-rich domains are common in the PDB structures with accession 3. STRUCTURAL EVALUATION number of 3K7L, 3DSL, 3HDB, 2ERQ, 2DW0 and 2E3X To elucidate their molecular structure and function, and other available PDB structures have only a reprolysin crystallographic studies have been carried out for the venoms domain. In addition to these domains, a reprolysin M12B of Naja atra, Bothrops moojeni, B. asper, B. jararaca, A. propeptide domain is predicted in the metalloproteinase of acutus, Crotalus adamanteus, C. atrox, Trimeresurus flavo- Gloydius halys (Agkistrodon halys) venom (Fig. 2a). We viridis, T. mucrosquamatus and Daboia russellii siamensis identified consensus motif HEXXHXUGUXHU and a bulky (Table 1). In general, SVMPs are structurally related to the hydrophobic core in the binding packets. Conserved domains mammalian membrane-bound ADAMs and other bacterial in those sequences were searched out with SMART 7.0 reprolysin subfamilies [24]. server [18] and NCBI-conserved domain database [19]. Catalytic site residue, Glu335 and 3 actives site residues, 3.1. Adamalysin II His334, His338 and His344, are located in a catalytic reprolysin domain of metalloproteinase from G. halys venom. The first crystallographic structure of adamalysin II In contrast, two highly conserved characteristic sequences from the snake venom of C. adamanteus was determined His142-Glu143-X-X-His146-X-X-Gly149-X-X-His152 and by Gomis-Ruth et al. [13]. Adamalysin II is mostly multi- Cys162-Ile163-Met164 are identified in acutolysin C [20]. domain protein, an ellipsoidal molecule with a shallow The sequentially conserved motifs
Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Metalloproteases): a Review
    Accepted Manuscript Therapeutic applications of collagenase (metalloproteases): A review Hamzeh Alipour, Abbasali Raz, Sedigheh Zakeri, Navid Dinparast Djadid PII: S2221-1691(16)30793-6 DOI: 10.1016/j.apjtb.2016.07.017 Reference: APJTB 369 To appear in: Asian Pacific Journal of Tropical Biomedicine Received Date: 14 February 2016 Revised Date: 27 February 2016 Accepted Date: 27 July 2016 Please cite this article as: Alipour H, Raz A, Zakeri S, Djadid ND, Therapeutic applications of collagenase (metalloproteases): A review, Asian Pacific Journal of Tropical Biomedicine (2016), doi: 10.1016/j.apjtb.2016.07.017. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Title: Therapeutic applications of collagenase (metalloproteases): A review Authors: Hamzeh Alipour 1,2,# , Abbasali Raz 1,# , Sedigheh Zakeri 1, Navid Dinparast Djadid 1* Affiliations: 1Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran 2Department of Medical Entomology, School of Health, Research Center for Health Sciences, Shiraz University of Medical Sciences, Shiraz, Iran Keywords: Enzyme Therapeutic application Collagenase MANUSCRIPT Non-invasive Metalloproteinase *Corresponding author: Navid Dinparast Djadid, Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Tel: +91 23573763 E-mail: [email protected] Foundation Project: Supported by Pasteur Institute of Iran and Iran National Science Foundation (Grant No.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Structural Basis of Mammalian Mucin Processing by the Human Gut O
    ARTICLE https://doi.org/10.1038/s41467-020-18696-y OPEN Structural basis of mammalian mucin processing by the human gut O-glycopeptidase OgpA from Akkermansia muciniphila ✉ ✉ Beatriz Trastoy 1,4, Andreas Naegeli2,4, Itxaso Anso 1,4, Jonathan Sjögren 2 & Marcelo E. Guerin 1,3 Akkermansia muciniphila is a mucin-degrading bacterium commonly found in the human gut that promotes a beneficial effect on health, likely based on the regulation of mucus thickness 1234567890():,; and gut barrier integrity, but also on the modulation of the immune system. In this work, we focus in OgpA from A. muciniphila,anO-glycopeptidase that exclusively hydrolyzes the peptide bond N-terminal to serine or threonine residues substituted with an O-glycan. We determine the high-resolution X-ray crystal structures of the unliganded form of OgpA, the complex with the glycodrosocin O-glycopeptide substrate and its product, providing a comprehensive set of snapshots of the enzyme along the catalytic cycle. In combination with O-glycopeptide chemistry, enzyme kinetics, and computational methods we unveil the molecular mechanism of O-glycan recognition and specificity for OgpA. The data also con- tribute to understanding how A. muciniphila processes mucins in the gut, as well as analysis of post-translational O-glycosylation events in proteins. 1 Structural Biology Unit, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, Spain. 2 Genovis AB, Box 790, 22007 Lund, Sweden. 3 IKERBASQUE, Basque Foundation for Science, 48013 ✉ Bilbao, Spain. 4These authors contributed equally: Beatriz Trastoy, Andreas Naegeli, Itxaso Anso.
    [Show full text]
  • Jararhagin ECD-Containing Disintegrin Domain: Expression in Escherichia Coli and Inhibition of the Platelet–Collagen Interaction
    Archives of Biochemistry and Biophysics Vol. 369, No. 2, September 15, pp. 295–301, 1999 Article ID abbi.1999.1372, available online at http://www.idealibrary.com on Jararhagin ECD-Containing Disintegrin Domain: Expression in Escherichia coli and Inhibition of the Platelet–Collagen Interaction Ana M. Moura-da-Silva,*,†,‡,1 Alex Lı´nica,* Maisa S. Della-Casa,* Aura S. Kamiguti,§ Paulo L. Ho,¶ Julian M. Crampton,† and R. David G. Theakston‡ *Laborato´rio de Imunopatologia and ¶Laborato´rio de Biotecnologia Molecular, Instituto Butantan, Av. Vital Brasil, 1500, 05503-900, Sa˜o Paulo, Brazil; §Department of Haematology, University of Liverpool, Prescot Street, Liverpool, L69 3BX, United Kingdom; and †Molecular Genetics Unit and ‡Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Pembroke Place, L3 5QA, Liverpool, United Kingdom Received May 17, 1999, and in revised form July 6, 1999 demonstrating that these antibodies recognize the Jararhagin, a hemorrhagin from Bothrops jararaca parent jararhagin molecule. Treatment of the fusion venom, is a soluble snake venom component compris- protein with enterokinase, followed by further cap- ing metalloproteinase and disintegrin cysteine-rich ture of the enzyme, resulted in a band of 30 kDa, the domains and, therefore, is structurally closely related expected size for jararhagin-C. Further purification of to the membrane-bound A Disintegrin And Metallo- the cleaved disintegrin using FPLC Mono-Q columns proteinase (ADAMs) protein family. Its hemorrhagic resulted in one fraction capable of efficiently inhibit- activity is associated with the effects of both metallo- ing collagen-induced platelet aggregation in a dose- proteinase and disintegrin domains; the metallopro- dependent manner (IC50 of 8.5 mg/ml).
    [Show full text]
  • Characterization of a Novel Metalloproteinase in Duvernoy's Gland of Rhabdophis Tigrinus Tigrinus
    The Journal of Toxicological Sciences, 157 Vol.31, No.2, 157-168, 2006 CHARACTERIZATION OF A NOVEL METALLOPROTEINASE IN DUVERNOY’S GLAND OF RHABDOPHIS TIGRINUS TIGRINUS Koji KOMORI1, Motomi KONISHI1, Yuji MARUTA1, Michihisa TORIBA2, Atsushi SAKAI2, Akira MATSUDA3, Takamitsu HORI3, Mitsuko NAKATANI4, Naoto MINAMINO4 and Toshifumi AKIZAWA1 1Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotogecho, Hirakata, Osaka 573-0101, Japan 2The Japan Snake Institute, 3318 Yabuzuka Ota, Gunma 379-2301, Japan 3Department of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan 4Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan (Received January 31, 2006; Accepted February 20, 2006) ABSTRACT — During the characterization of hemorrhagic factor in venom of Rhabdophis tigrinus tigri- nus, so-called Yamakagashi in Japan, one of the Colubridae family, a novel metalloproteinase with molec- ular weight of 38 kDa in the Duvernoy’s gland of Yamakagashi was identified by gelatin zymography and by monitoring its proteolytic activity using a fluorescence peptide substrate, MOCAc-PLGLA2pr(Dnp)AR-NH2, which was developed for measuring the well-known matrix metalloproteinase (MMP) activity. After purification by gel filtration HPLC and/or column switch HPLC system consisting of an affin- ity column, which was immobilized with a synthetic BS-10 peptide (MQKPRCGVPD) originating from propeptide domain of MMP-7 and a reversed-phase column, the N-terminal amino acid sequence of the 38 kDa metalloproteinase was identified as FNTFPGDLK which shared a high homology to Xenopus MMP-9. The 38 kDa metalloproteinase required Zn2+ and Ca2+ ions for its proteolytic activity.
    [Show full text]
  • Final Program N
    XXII Congress The International Society on Thrombosis and Haemostasis B July 11-16 2009 O 55th Annual Meeting S of the Scientific and Standardization Committee of the ISTH T O Final Program N Boston - July 11-16 2009 XXII Congress of the International Society on Thrombosis and Haemostasis 2009 Table ISTH of Contents Venue and Contacts 2 Wednesday 209 Welcome Messages 3 – Plenary Lectures 210 Committees 7 – State of the Art Lectures 210 Congress Awards and Grants 15 – Abstract Symposia Lectures 212 Other Meetings 19 – Oral Communications 219 – Posters 239 ISTH Information 20 Program Overview 21 Thursday 305 SSC Meetings and – Plenary Lectures 306 Educational Sessions 43 – State of the Art Lectures 306 – Abstract Symposia Lectures 309 Scientific Program 89 – Oral Communications 316 Monday 90 – Posters 331 – Plenary Lectures 90 Nursing Program 383 – State of the Art Lectures 90 Special Symposia 389 – Abstract Symposia Lectures 92 Satellite Symposia 401 – Oral Communications 100 – Posters 118 Technical Symposia Sessions 411 Exhibition and Sponsors 415 Tuesday 185 – Plenary Lectures 186 Exhibitor and Sponsor Profiles 423 – State of the Art Lectures 186 Congress Information 445 – Abstract Symposia Lectures 188 Map of BCEC 446 – Oral Communications 196 Hotel and Transportation Information 447 ISTH 2009 Congress Information 452 Boston Information 458 Social Events 463 Excursions 465 Authors’ Index 477 1 Venue & Contacts Venue Boston Convention & Exhibition Center 415 Summer Street - Boston, Massachusetts 02210 - USA Phone: +1 617 954 2800 - Fax: +1 617 954 3326 The BCEC is only about 10 minutes by taxi from Boston Logan International Airport. The 2009 Exhibition is located in Hall A and B of the Exhibit Level of the BCEC, along with posters and catering.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0305517 A1 Griffin Et Al
    US 2008O305517A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0305517 A1 Griffin et al. (43) Pub. Date: Dec. 11, 2008 (54) TRANSGLUTAMINASE CROSSLINKED (30) Foreign Application Priority Data COLLAGEN BOMATERAL FOR MEDICAL MPLANT MATERALS Sep. 10, 2004 (GB) ................................... O42O091.1 (75) Inventors: Martin Griffin, Nottingham (GB); Publication Classification Russell Collighan, Birmingham (51) Int. Cl. (GB); David Chau, Birmingham CI2N 5/06 (2006.01) (GB); Elisabetta Verderio CI2P 2L/02 (2006.01) Edwards, Nottingham (GB) A6IF 2/28 (2006.01) A6F I3/00 (2006.01) Correspondence Address: FSH & RICHARDSON PC (52) U.S. Cl. ..................... 435/68.1; 435/395; 623/16.11; 602/48 P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022 (US) (57) ABSTRACT (73) Assignee: ASTON UNIVERSITY, The present invention provides a method for producing an Birmingham, West Midlands (GB) improved biomaterial comprising treating a collagen bioma terial with a transglutaminase under conditions which permit (21) Appl. No.: 111574,918 the formation of cross-links within the collagen. Preferably, the transglutaminase is a tissue transglutaminase, a plasma (22) PCT Filed: Sep. 12, 2005 transglutaminase or a microbial transglutaminase. In a pre ferred embodiment, the collagen biomaterial further com (86). PCT No.: PCT/GBOS/O352O prises a cell adhesion factor, Such as fibronectin. The inven tion further provides biomaterials obtainable by the methods S371 (c)(1), of the invention, and medical implants and wound dressings (2), (4) Date: Aug. 11, 2008 comprising the same. -- Collagen (3 mg/ml) -O- Coll-mTG (50ug/ml) -v- Co-mTG (250ug/ml) -v- Coll-mTG-R281 -- Coll-R281 O 5 10 15 20 25 Time (min) Patent Application Publication Dec.
    [Show full text]
  • Structural Interaction of Natural and Synthetic Inhibitors with the Venom Metalloproteinase, Atrolysin C
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 8447-8451, August 1994 Biochemistry Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d) (coilagenase/inhibltor complex/crystafography/metastasis) DACHUAN ZHANG*, ISTVAN BOTOS*, FRANZ-XAVER GOMIS-ROTHtt, RONALD DOLL§, CHRISTINE BLOOD§, F. GEORGE NJOROGE§, JAY W. Fox¶, WOLFRAM BODEt, AND EDGAR F. MEYER* 11 *Biographics Laboratory, Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843; tMax Planck Institute of Biochemistry, D-82152 Martinsried, Germany; §Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033; IBiomolecular Research Facility, University of Virginia Health Sciences Center, Charlottesville, VA 22908 Communicated by Derek H. R. Barton, May 20, 1994 ABSTRACT The structure of the metalloproteinase and 80% sequence similarity to Ht-d) has been described (12), as hemorrhagic toxin atrolysin C form d (EC 3.4.24.42), from the was the native digestive MP, astacin (13). A high degree of venom ofthe western diamondback rattlesnake Crotalus atrox, tertiary structure conservation among the astacin, reprol- has been determined to atomic resolution by x-ray crystallo- ysin, serralysins, and the MMP subfamilies is observed (9, 14) graphic methods. This study illuminates the nature ofinhibitor at the active site, suggesting that the structural principles that binding with natural (<Glu-Asn-Trp, where <Glu is pyroglu- govern the interaction of substrates and inhibitors with tamic acid) and synthetic (SCH 47890) ligands. The primary members of these subfamilies are likely to be similar if not specificity pocket is exceptionally deep; the nature of inhibitor identical. Substrates and synthetic inhibitors of the MMPs and productive substrate binding is discussed.
    [Show full text]
  • Novel Catalytically-Inactive PII Metalloproteinases from a Viperid Snake Venom with Substitutions in the Canonical Zinc-Binding Motif
    toxins Article Novel Catalytically-Inactive PII Metalloproteinases from a Viperid Snake Venom with Substitutions in the Canonical Zinc-Binding Motif Erika Camacho 1, Libia Sanz 2, Teresa Escalante 1, Alicia Pérez 2, Fabián Villalta 1, Bruno Lomonte 1, Ana Gisele C. Neves-Ferreira 3, Andrés Feoli 1, Juan J. Calvete 2,4, José María Gutiérrez 1 and Alexandra Rucavado 1,* 1 Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501, Costa Rica; [email protected] (E.C.); [email protected] (T.E.); [email protected] (F.V.); [email protected] (B.L.); [email protected] (A.F.); [email protected] (J.M.G.) 2 Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia 46010, Spain; [email protected] (L.S.); [email protected] (A.P.); [email protected] (J.J.C.) 3 Laboratório de Toxinologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil; [email protected] 4 Departamento de Biotecnología, Universidad Politécnica de Valencia, Valencia 46022, Spain * Correspondence: [email protected]; Tel.: +506-25117876 Academic Editor: Nicholas R. Casewell Received: 12 September 2016; Accepted: 30 September 2016; Published: 12 October 2016 Abstract: Snake venom metalloproteinases (SVMPs) play key biological roles in prey immobilization and digestion. The majority of these activities depend on the hydrolysis of relevant protein substrates in the tissues. Hereby, we describe several isoforms and a cDNA clone sequence, corresponding to PII SVMP homologues from the venom of the Central American pit viper Bothriechis lateralis, which have modifications in the residues of the canonical sequence of the zinc-binding motif HEXXHXXGXXH.
    [Show full text]
  • Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 203639, 19 pages http://dx.doi.org/10.1155/2014/203639 Review Article Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy Leonardo A. Calderon,1 Juliana C. Sobrinho,1 Kayena D. Zaqueo,1 Andrea A. de Moura,1 Amy N. Grabner,1 Maurício V. Mazzi,2 Silvana Marcussi,3 Auro Nomizo,4 CarlaF.C.Fernandes,1 Juliana P. Zuliani,1 Bruna M. A. Carvalho,5 Saulo L. da Silva,5 Rodrigo G. Stábeli,1 and Andreimar M. Soares1 1 Centro de Estudos de Biomoleculas´ Aplicadas aSa` ude,´ CEBio, Fundac¸ao˜ Oswaldo Cruz, Fiocruz Rondoniaˆ e Departamento de Medicina, Universidade Federal de Rondonia,ˆ UNIR, Porto Velho, RO, Brazil 2 Fundac¸ao˜ Herm´ınio Ometto, UNIARARAS, Nucleo´ de Cienciasˆ da Saude-NUCISA,´ 13607-339 Araras, SP, Brazil 3 Departamento de Qu´ımica, Universidade Federal de Lavras, UFLA, 37200-000 Lavras, MG, Brazil 4 Departamento de Analises´ Cl´ınicas, Toxicologicas´ e Bromatologicas,´ Faculdade de Cienciasˆ Farmaceuticasˆ de Ribeirao˜ Preto, Universidade de Sao˜ Paulo, USP, Ribeirao˜ Preto, SP, Brazil 5 Departamento de Qu´ımica, Biotecnologia e Engenharia de Bioprocessos, Universidade Federal de Sao˜ Joao˜ del Rei, UFSJ, Campus Alto paraopeba, Ouro Branco, MG, Brazil Correspondence should be addressed to Andreimar M. Soares; [email protected] Received 20 September 2013; Revised 7 December 2013; Accepted 8 December 2013; Published 13 February 2014 Academic Editor: Fernando Albericio Copyright © 2014 Leonardo A. Calderon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease
    pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online September 6, 2017 https://doi.org/10.5534/wjmh.17033 Review Article Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease: Review of a Minimally Invasive Treatment Option Andrew T Gabrielson, Laith M Alzweri, Wayne JG Hellstrom Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA Peyronie’s disease (PD) is an inflammatory disorder characterized by an abnormal collagen deposition in the tunica albuginea of the penis, leading to fibrous and non-compliant plaques that can impede normal erection. Although pharmacological treatments are available, only intralesional injection therapy and surgical reconstruction have demonstrated tangible clinical efficacy in the management of this condition. Intralesional injection of collagenase clostridium histolyticum (CCH) has come to the forefront of minimally invasive treatment of PD. In this review, the authors provide an update on the safety, efficacy, and indications for CCH. The efficacy of CCH will be assessed on the basis of improvement in the severity of penile fibrosis, curvature, and pain. Numerous well-designed clinical trials and post-approval studies involving more than 1,500 patients have consistently demonstrated the efficacy and tolerability of CCH in the treatment of PD. CCH significantly decreases penile curvature and plaque consistency, as well as improves quality of life. Post-approval studies continue to demonstrate the efficacy of CCH despite broader inclusion criteria for treatment, such as the case with acute phase disease and atypical plaque deformities (i.e., ventral plaques, hourglass narrowing). CCH continues to be the gold standard for non-surgical management of stable phase PD, in the absence of strong evidence supporting oral therapy agents and ongoing evaluation of extracorporeal shockwave therapy.
    [Show full text]